← Back to ResearchAOD-9604 glass vial with vintage 1990s lab equipment and modern instruments, warm amber lighting on dark background

AOD-9604: The Forgotten Fat Loss Peptide (Research Guide)

Research chemical. Not for human administration. AOD-9604 is supplied strictly for in vitro and preclinical research use only. See our research peptides sourcing guide for quality considerations.

Contents

  1. The HGH Fragment That Missed Its Moment
  2. History & Origin: Metabolic Pharmaceuticals and the 1990s
  3. Molecular Mechanism: How AOD-9604 Differs From Full HGH
  4. Available Clinical Data: What Phase 2 Actually Showed
  5. AOD-9604 vs GLP-1 Agonists: An 8-Dimension Comparison
  6. Why AOD-9604 Remains Relevant in 2026 Research
  7. Reconstitution and Storage for Research Use
  8. FAQ

The HGH Fragment That Missed Its Moment

Thirty years before Wegovy became a household name, a small Australian biotech had already identified a peptide fragment of human growth hormone capable of triggering fat-cell lipolysis without the metabolic downsides of full HGH. The compound was AOD-9604 — Anti-Obesity Drug 9604 — and in another timeline, it might have been the first pharmaceutical-grade fat loss peptide to reach market approval.

It didn't. And the story of why tells you a great deal about how pharmaceutical development actually works, what the science of lipolysis looked like before GLP-1 agonists rewrote the field, and why researchers today are revisiting a peptide that spent the better part of two decades in obscurity.

The mechanism is genuinely interesting: AOD-9604 targets adipocyte lipolysis through β3-adrenergic receptor upregulation — a peripheral, fat-tissue-specific pathway that doesn't touch the GH receptor, doesn't elevate IGF-1, and doesn't produce the insulin resistance you'd expect from exogenous growth hormone. In a pre-semaglutide world, that profile was remarkable. In 2026, it looks like an entirely different tool — one with a far more limited efficacy ceiling than GLP-1 agonists, but a mechanistic specificity that has renewed niche relevance.

This guide covers the full picture: the origin story, the molecular mechanism, the real clinical data, the comparison against modern GLP-1 agonists, and what the current research landscape actually looks like.

History & Origin: Metabolic Pharmaceuticals and the 1990s

The Discovery: Finding the Lipolytic Fragment

The origin of AOD-9604 sits within a line of research going back to the 1980s, when researchers began investigating whether the diverse biological effects of human growth hormone — anabolism, lipolysis, IGF-1 stimulation, insulin resistance — could be dissected at the structural level. The working hypothesis: different regions of the HGH molecule might be responsible for different activities.

This turned out to be correct. The C-terminal region of HGH, specifically amino acids 176–191, had been observed in earlier work to carry most of the lipolytic activity of the full molecule. Metabolic Pharmaceuticals, a Melbourne-based biotech, built on this observation through the 1990s under the scientific direction of Professor Fu Man Ng at Monash University. The team synthesized a modified version of this fragment — adding a tyrosine residue at the N-terminus to improve stability — and designated the resulting 16-amino acid peptide AOD-9604.

Timeline: AOD-9604 from Discovery to 2026

YearEvent
~1990sC-terminal HGH fragment lipolytic activity characterized at Monash University (Ng lab)
2001First major publications: Heffernan et al. demonstrate AOD9604 reduces body weight in obese mice via fat oxidation and β3-AR expression (PMID 11673763, PMID 11713213)
2002Phase IIa clinical trials initiated by Metabolic Pharmaceuticals
2004Wilding J. (Curr Opin Investig Drugs) reviews Phase IIa progress: compound in active development for obesity (PMID 15134286)
2007Phase 2b results — modest weight loss, primary endpoint not met
2010Metabolic Pharmaceuticals pivots; active clinical development as anti-obesity drug discontinued
2013Cox et al. characterize metabolism and detection in doping context; WADA places AOD-9604 on monitoring list
2014FDA grants GRAS status for cosmetic applications
2015Research expands into cartilage/osteoarthritis models (Kwon & Park, PMID 26275694)
2024–2026Renewed research interest as potential GLP-1 stack candidate and body recomposition tool

Why Development Was Abandoned

Metabolic Pharmaceuticals advanced AOD-9604 through Phase IIa and then Phase IIb trials, but the clinical results told a humbling story. The peptide produced measurable but modest weight reductions in human subjects — on the order of 1–2 kg over extended treatment periods, far short of the efficacy threshold needed to justify a Phase III programme in obesity.

The reasons are mechanistic: AOD-9604 operates via peripheral lipolysis, specifically targeting adipocyte β3-adrenergic signalling. This is a real effect — the preclinical data was robust. But it's a limited one. Fat loss from enhanced lipolysis without concurrent appetite suppression or energy intake reduction faces a straightforward ceiling: the body compensates. Without the central appetite effects that make GLP-1 agonists so effective, patients eating normally will partially compensate for increased fat oxidation through normal metabolic adjustment.

Molecular Mechanism: How AOD-9604 Differs From Full HGH

Structure and Chemistry

AOD-9604 is a 16-amino acid synthetic peptide corresponding to the C-terminal fragment of human growth hormone (residues 177–191 of the mature HGH sequence), with an additional tyrosine added at the N-terminus for stability.

Technical specifications:

  • Full name: Anti-Obesity Drug 9604 (HGH fragment 177–191 + N-terminal Tyr)
  • Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
  • Residues: 16 amino acids (15 from HGH fragment + 1 Tyr N-terminal addition)
  • Molecular weight: 1815.07 g/mol
  • CAS number: 221231-10-3
  • Disulfide bond: Cys7–Cys14 (intramolecular, critical for bioactive conformation)
  • Subcutaneous half-life: ~30 minutes
  • GH receptor agonism: None
Abstract molecular visualization of HGH fragment 177-191 peptide structure on dark background, electric blue bioluminescent bonds

The Critical Distinction: No GH Receptor Interaction

The most scientifically important fact about AOD-9604 is what it doesn't do: it does not bind the GH receptor (GHR). Heffernan et al. (2001, PMID 11673763) confirmed this using BaF-BO3 cells transfected with the hGH receptor — AOD-9604 showed no competitive binding and did not induce cell proliferation through the GH receptor pathway.

This distinction is foundational. Full exogenous HGH produces:

  • Elevated IGF-1 (anabolic + proliferative)
  • Insulin resistance (glucose counter-regulation)
  • Potential adverse effects on cell proliferation
  • Acromegalic risk with chronic supraphysiological dosing

AOD-9604 produces none of these. In the same preclinical models where full HGH suppressed insulin secretion and induced hyperglycaemia, AOD-9604 had no effect on glucose metabolism (Heffernan et al. 2001, PMID 11673763). The lipolytic activity was preserved; the metabolic toxicity of full HGH was not.

The β3-Adrenergic Mechanism

What AOD-9604 does do is upregulate β3-adrenergic receptor (β3-AR) expression in adipose tissue. Heffernan et al. (2001, Endocrinology, PMID 11713213) showed:

  1. In obese mice, β3-AR RNA expression is chronically suppressed
  2. AOD-9604 treatment restored β3-AR expression to levels comparable with lean control mice
  3. The weight-loss effect was partially mediated through β3-AR, though not exclusively so
  4. In β3-AR knockout mice, chronic AOD-9604 treatment failed to produce the body weight changes seen in wild-type mice — confirming β3-AR involvement

The β3-AR is the primary lipolytic adrenergic receptor in adipocytes. Its upregulation creates conditions for enhanced catecholamine-driven lipolysis — free fatty acid release from triglycerides stored in adipose tissue. The same study showed correlated increases in plasma glycerol (a direct marker of lipolysis) and reduced body fat mass.

This is a peripheral mechanism. AOD-9604 doesn't cross the blood-brain barrier in any meaningful way, doesn't interact with hypothalamic appetite circuits, and doesn't produce the nausea, satiety, or food aversion that GLP-1 agonists drive through central pathways. The lipolysis is real; the appetite suppression is absent.

IGF-1 Independence

Unlike full HGH, AOD-9604 research has consistently shown no elevation in IGF-1 levels. This is mechanistically expected — IGF-1 production requires hepatic GH receptor stimulation, which AOD-9604 bypasses entirely. The implication for research models: AOD-9604 can be used to study peripheral lipolytic pathways without the confounding anabolic/proliferative effects that IGF-1 elevation introduces.

Available Clinical Data: What Phase 2 Actually Showed

Phase IIa: Proof of Concept (2002–2004)

Metabolic Pharmaceuticals initiated Phase IIa trials around 2002. The preliminary clinical data, reviewed by Wilding (Curr Opin Investig Drugs, 2004, PMID 15134286), indicated that the compound had an acceptable safety profile and showed initial signals of metabolic activity in overweight subjects. At this stage, the programme was deemed sufficiently promising to advance.

Phase IIb: The Pivotal Results

The Phase IIb trial results told a more complicated story. A randomized, placebo-controlled study enrolled overweight subjects and assessed AOD-9604 at multiple doses over 12 weeks. The key findings:

  • Weight loss: Statistically significant versus placebo, but modest in absolute terms — approximately 0.5–2.0 kg depending on dose and timepoint
  • Safety: Excellent — no significant adverse events, no glucose disruption, no IGF-1 elevation
  • Mechanism confirmation: Plasma lipid profiles and glycerol markers consistent with enhanced lipolysis

The primary endpoint for regulatory approval was not met. In an obesity indication, regulatory bodies typically require ≥5% mean body weight loss over placebo, or ≥5% loss in ≥35% of subjects. AOD-9604 did not reach this threshold. The business case for a Phase III programme evaporated.

Anti-Doping Research and Metabolism Characterization

Cox et al. (Drug Test Anal., 2015, PMID 25208511) characterized the in vitro metabolism of AOD-9604, identifying six metabolites after incubation in serum and urine. The most stable metabolite — CRSVEGSCG — was significantly more stable than the parent compound, potentially extending the detection window.

Orlovius et al. (Drug Test Anal., 2013, PMID 24124033) confirmed that AOD-9604 does not interfere with the WADA hGH isoform immunoassay — meaning AOD-9604 use cannot be detected by standard HGH doping tests, requiring specific assays targeting the fragment or its metabolites.

Cartilage and Joint Research

A notably different research application emerged in 2015: Kwon and Park (Ann Clin Lab Sci., 2015, PMID 26275694) investigated intra-articular injection of AOD-9604 in a rabbit osteoarthritis model. The study found that AOD-9604 enhanced cartilage regeneration compared to controls, and that combination with hyaluronic acid produced superior outcomes than either treatment alone — an area that remains underexplored in the literature.

AOD-9604 vs GLP-1 Agonists: An 8-Dimension Comparison

This is the comparison most research summaries avoid making explicitly. Here it is directly — the full mechanistic and clinical picture.

↔ Scroll horizontally to view the full table on mobile.

DimensionAOD-9604Semaglutide (GLP-1)Retatrutide (Triple)
Primary mechanismβ3-AR upregulation → peripheral lipolysisGLP-1R agonism → central appetite suppression + GI motilityGLP-1R + GIPR + GCGR → triple receptor engagement
Clinical weight loss~0.5–2 kg (Phase 2b, threshold not met)~15% BW loss at 2.4 mg/week (STEP trials)~24.2% BW loss at 12 mg/week (Phase 2)
Appetite suppressionNone (peripheral only)Significant (hypothalamic satiety circuits)Significant (GLP-1R + GIPR central)
IGF-1 effectNoneNoneNone
GH receptor bindingNoneN/AN/A
Half-life~30 min (subQ)~7 days~6 days
Primary side effectsMinimal (no nausea, no glucose disruption)GI: nausea, vomiting, diarrhoea (dose-dependent)GI: nausea, vomiting; HR increase (GCGR)
Regulatory statusNot approved; GRAS cosmetic FDA 2014; RUO onlyApproved (Ozempic/Wegovy — T2D + obesity)Phase 3 (TRIUMPH programme); RUO only
Best research modelAdipocyte lipolysis; β3-AR studies; OA models; recompositionObesity models; T2D; GLP-1R pathwayObesity + metabolic disease; triple agonism
Stack potentialPotential complement to GLP-1 (additive peripheral mechanism)N/A (standalone approval)Emerging dual lipolytic stack hypothesis

What the Comparison Actually Means

The efficacy gap is large and undeniable. GLP-1 agonists produce 15–24% body weight reduction; AOD-9604 produced 0.5–2 kg in Phase 2b. That's not a refinement of the same tool — it's a categorically different magnitude.

But the comparison misses the point if framed as direct competition. AOD-9604 and GLP-1 agonists operate through entirely different mechanisms. For models specifically examining adipocyte biology, β3-AR function, or fat oxidation kinetics, AOD-9604 provides mechanistic specificity that semaglutide cannot — without contaminating the readout with central appetite effects.

For deep context on GLP-1 class research compounds, see our retatrutide research guide and tirzepatide research protocol.

Why AOD-9604 Remains Relevant in 2026 Research

1. The Stack Hypothesis: Complementary Mechanisms

The most discussed application in 2026 research circles is the theoretical combination of AOD-9604 with GLP-1 agonists. The logic is mechanistically coherent: GLP-1 agonists reduce energy intake through central satiety signalling; AOD-9604 increases lipolysis in adipose tissue through peripheral β3-AR upregulation. These pathways do not overlap.

In preclinical models where this combination has been tested informally, the additive hypothesis holds. Whether this produces clinically meaningful additive weight loss requires proper controlled research — but the mechanistic rationale is sound and mirrors the logic behind multi-mechanism obesity pharmacology more broadly.

2. FDA GRAS Status (2014): What It Actually Means

In 2014, the FDA granted AOD-9604 GRAS (Generally Recognized as Safe) status for cosmetic (topical) applications. This is sometimes mischaracterized as broad approval — it is not. GRAS applies specifically to topical use and does not confer any status regarding injectable research use or human administration. What it signals: the toxicological profile at cosmetic doses is acceptable, consistent with Phase 2 safety data.

3. Cartilage Research Applications

The osteoarthritis research of Kwon and Park (2015, PMID 26275694) opened a different research avenue. AOD-9604's demonstrated cartilage-protective effects in rabbit joint models suggest mechanisms beyond simple adipocyte lipolysis. Whether these effects relate to β3-AR pathway, local growth factor modulation, or something else is not yet established — a genuine research gap with potential.

4. No Central Effects: A Research Advantage

For models where CNS effects would confound the experiment, AOD-9604 offers clean peripheral action. GLP-1 agonists engage hypothalamic circuits, vagal afferent pathways, and dopaminergic reward systems — significant confounders in experiments measuring behavioral or CNS outputs. AOD-9604 doesn't interact with these pathways, making it a cleaner tool for isolated adipocyte or lipid metabolism studies.

Reconstitution and Storage for Research Use

AOD-9604 is typically supplied as a lyophilized white powder in sealed glass vials. The following represents standard laboratory practice for peptide reconstitution.

See our complete guide to peptide reconstitution for research use and how to read a peptide Certificate of Analysis.

Reconstitution

Recommended solvent: Bacteriostatic water (0.9% benzyl alcohol in sterile water for injection) for multi-use preparations. Sterile water for injection for single-use.

Procedure:

  1. Allow vial to equilibrate to room temperature (15–20 minutes) before opening
  2. Clean vial stopper with 70% isopropanol wipe; allow to air dry
  3. Add solvent slowly along the vial wall, not directly onto the lyophilized cake
  4. Gently swirl (do not vortex or shake) until fully dissolved
  5. Solution should be clear and colorless; discard if cloudy or particulate

Stability and Storage

ConditionDuration
Lyophilized, −20°C24 months (manufacturer typical)
Reconstituted with bacteriostatic water, 2–8°CUp to 28 days
Reconstituted with sterile water, 2–8°C5–7 days maximum
Reconstituted, room temperatureSame-day use only
Multiple freeze-thaw cyclesAvoid; aliquot before freezing

Key considerations: AOD-9604 contains a disulfide bond (Cys7–Cys14) critical for bioactive conformation — avoid reducing agents in experimental buffers. The short half-life (~30 min in physiological conditions) requires frequent sampling or continuous infusion protocols for accurate pharmacokinetic characterization. HPLC purity ≥98% is standard; verify via CoA before use.

For sourcing guidance, see our research peptides buying guide for 2026. AOD-9604 is not currently listed in the UNIK LAB catalog — check back for availability updates.

FAQ

What is AOD-9604 and how does it differ from full HGH?

AOD-9604 (CAS 221231-10-3) is a 16-amino acid synthetic peptide derived from the C-terminal fragment of human growth hormone (residues 177–191), with an N-terminal tyrosine added for stability. Unlike full HGH, it does not bind the GH receptor, does not elevate IGF-1, and does not produce insulin resistance. Its activity is limited to peripheral adipose tissue, where it upregulates β3-adrenergic receptor expression and stimulates lipolysis.

What did clinical trials show for AOD-9604 weight loss?

Phase IIa and IIb trials showed statistically significant but modest weight reduction — approximately 0.5–2 kg versus placebo over 12 weeks. The compound failed to meet the clinically meaningful threshold required for regulatory approval in obesity (≥5% mean body weight loss over placebo). Safety was excellent: no significant adverse events, no IGF-1 elevation, no glucose disruption.

Why was AOD-9604 development discontinued?

The primary endpoint of meaningful clinical weight loss was not met in Phase IIb. Without a strong efficacy signal, advancing to the $300–500M+ cost of Phase III was not commercially viable. The peripheral-only mechanism — lipolysis without appetite suppression — faces a compensatory ceiling in subjects eating ad libitum.

How does AOD-9604 compare to semaglutide for fat loss research?

The efficacy gap is substantial: semaglutide produces ~15% body weight loss in clinical trials; AOD-9604 produced less than 2 kg in Phase 2b. The mechanisms are entirely different. For research applications examining peripheral lipolysis, β3-AR function, or fat oxidation kinetics without CNS confounders, AOD-9604 offers mechanistic specificity that GLP-1 agonists cannot provide without contaminating the readout.

What is the GRAS FDA status of AOD-9604?

The FDA granted AOD-9604 GRAS status in 2014 specifically for cosmetic (topical) applications. This does not constitute approval for injectable research use or human administration. It reflects an acceptable toxicological profile at cosmetic doses, consistent with the Phase 2 clinical safety record.

Can AOD-9604 be detected in standard HGH doping tests?

No. Orlovius et al. (2013, PMID 24124033) confirmed that AOD-9604 does not interfere with the WADA hGH isoform immunoassay. Detection requires specific assays targeting AOD-9604 or its metabolites. Cox et al. (2015, PMID 25208511) characterized six metabolites, with CRSVEGSCG identified as the most stable marker.

Is AOD-9604 approved for human use?

No. AOD-9604 is not approved by any regulatory authority — FDA, EMA, TGA, Health Canada, or equivalent — for human therapeutic use. It is available strictly as a research-use-only compound for in vitro and preclinical research.

What research applications remain relevant for AOD-9604 in 2026?

Current relevance includes: (1) adipocyte lipolysis pathway studies isolating β3-AR function without central confounders; (2) osteoarthritis/cartilage models following Kwon & Park 2015 (PMID 26275694); (3) anti-doping detection methodology; (4) theoretical combination studies with GLP-1 agonists; (5) body recomposition models where appetite suppression would confound the design.

References

  1. Heffernan MA et al. "Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment." Int J Obes Relat Metab Disord. 2001 Oct;25(10):1442–9. PMID 11673763
  2. Heffernan M et al. "The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice." Endocrinology. 2001 Dec;142(12):5182–9. PMID 11713213
  3. Wilding J. "AOD-9604 Metabolic." Curr Opin Investig Drugs. 2004 Apr;5(4):436–40. PMID 15134286
  4. Orlovius AK et al. "AOD-9604 does not influence the WADA hGH isoform immunoassay." Drug Test Anal. 2013 Nov–Dec;5(11–12):850–2. PMID 24124033
  5. Cox HD et al. "Detection and in vitro metabolism of AOD9604." Drug Test Anal. 2015 Jan;7(1):31–8. PMID 25208511
  6. Kwon DR, Park GY. "Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model." Ann Clin Lab Sci. 2015 Summer;45(4):426–32. PMID 26275694

Content produced by UNIK LAB Research Team. For research use only. This article is informational and does not constitute medical advice. AOD-9604 is not approved for human therapeutic use by any regulatory authority.